2023: The year in cardiovascular disease - the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?
{"title":"2023: The year in cardiovascular disease - the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?","authors":"Maciej Banach, Stanisław Surma, Peter P Toth","doi":"10.5114/aoms/174743","DOIUrl":null,"url":null,"abstract":"In 2023 there are still even 75% of patients over the LDL-C target, and hypercholesterolemia is the most common and the worst monitored CVD risk factor. How it is possible, considering the knowledge we have on the role of cholesterol in the process of atherosclerosis, ASCVD and its complications, on the methods of lipid disorders diagnosis, prevention, and treatment. Nowadays, almost 4 million deaths per year are attributed to LDL-C, and even 2/3 of all CVD deaths to ASCVD, therefore hypothetically we should easily prevent few to several million of deaths with early diagnosis, and early and intensive non-pharmacological and pharmacological therapies. Moreover, lipidology is the area with the highest number of new and ongoing trials with new medications that have already appeared and will soon be available. Therefore, we have no doubt that year 2023 should be called the year of new and prospective LLTs.","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"22 10","pages":"0"},"PeriodicalIF":3.0000,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Medical Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/aoms/174743","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
In 2023 there are still even 75% of patients over the LDL-C target, and hypercholesterolemia is the most common and the worst monitored CVD risk factor. How it is possible, considering the knowledge we have on the role of cholesterol in the process of atherosclerosis, ASCVD and its complications, on the methods of lipid disorders diagnosis, prevention, and treatment. Nowadays, almost 4 million deaths per year are attributed to LDL-C, and even 2/3 of all CVD deaths to ASCVD, therefore hypothetically we should easily prevent few to several million of deaths with early diagnosis, and early and intensive non-pharmacological and pharmacological therapies. Moreover, lipidology is the area with the highest number of new and ongoing trials with new medications that have already appeared and will soon be available. Therefore, we have no doubt that year 2023 should be called the year of new and prospective LLTs.
期刊介绍：
Archives of Medical Science (AMS) publishes high quality original articles and reviews of recognized scientists that deal with all scientific medicine. AMS opens the possibilities for young, capable scientists. The journal would like to give them a chance to have a publication following matter-of-fact, professional review by outstanding, famous medical scientists. Thanks to that they will have an opportunity to present their study results and/or receive useful advice about the mistakes they have made so far.
The second equally important aim is a presentation of review manuscripts of recognized scientists about the educational capacity, in order that young scientists, often at the beginning of their scientific carrier, could constantly deepen their medical knowledge and be up-to-date with current guidelines and trends in world-wide medicine. The fact that our educational articles are written by world-famous scientists determines their innovation and the highest quality.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
